Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas

A Single-Center, Open-Label, Phase I Study of Single-Agent GMX1777 Administered as a 24-Hour Infusion Every 3 Weeks to Patients With Refractory Solid Tumors or Lymphomas

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00457574

Enrollment

Registered

2007-04-06

Start date

2007-03-31

Completion date

2010-08-31

Last updated

2013-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors and Lymphomas

Brief summary

GMX1777 is a water-soluble, intravenously-administered prodrug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.

Detailed description

This is a single-center, open-label, Phase I study of single-agent GMX1777 administered every 3 weeks to patients with CLL, MM, refractory solid tumors or lymphomas. No investigational or commercial agents or therapies other than those described may be administered with the intent to treat the patient's malignancy.

Interventions

DRUGGMX1777

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients must have a histologically or cytologically confirmed solid tumor or lymphoma * No limitations on allowable type and amount of prior therapy. * Patients must have a life expectancy of greater than 8 weeks * Patients must have normal organ and marrow function * Patients must be willing to submit blood sampling for planned PK analysis * Patients must have the ability to understand and willingness to sign a written informed consent form

Exclusion criteria

* No other agents or therapies administered with the intent to treat malignancy * Patients with prior exposure to GMX1777 or GMX1778 * Uncontrolled, intercurrent illness * Pregnant women and women who are breast feeding

Design outcomes

Primary

Measure	Time frame
Determine the recommended Phase II dose; Characterize the dose-limiting toxicities; Determine the pharmacokinetic parameters	52 weeks

Secondary

Measure	Time frame
Describe observed tumor responses	52 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026